EUCTR2013-004739-55-DK进行中（未招募）1 期
A randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients with iron overload
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent/assent before any study-specific procedures. Consent will be obtained from parent(s) or legal guardians. Investigators will also obtain assent of patients according to local guidelines.
- •2. Male and female children and adolescents aged = 2 and < 18 years.
- •3. Any transfusion-dependent anemia associated with iron overload requiring iron chelation therapy and with a history of transfusion of approximately 20 PRBC units and a treatment goal to reduce iron burden (300mL PRBC = 1 unit in adults whereas 4 ml/kg PRBC is considered 1 unit for children).
- •4. Serum ferritin > 1000 ng/mL, measured at screening Visit 1 and screening Visit 2 (the mean value will be used for eligibility criteria).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 240
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Creatinine clearance below the contraindication limit in the locally approved prescribing information. Creatinine clearance will be estimated from serum creatinine (using the Schwartz formula) at screening Visit 1 and screening Visit 2 and the mean value will be used for eligibility criteria.
- •2. Serum creatinine > 1.5 xULN at screening measured at screening Visit 1 and screening Visit 2 (the mean value will be used for eligibility criteria).
- •3. ALT and/or AST > 3.0 x ULN.
- •4. Liver disease with severity of Child-Pugh class B or C.
- •5. Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5 mg/mg in a non-first void urine sample at screening Visit 1 or screening Visit 2.
- •6. Patients with significant impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
- •Other exclusion criteria as per full protocol may apply.
研究者
相似试验
进行中（未招募）
1 期
A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improveddeferasirox formulation (film-coated tablet)transfusion-dependent thalassemia or myelodysplastic syndrome at very low, low or intermediate (int-1) riskMedDRA version: 17.0Level: LLTClassification code 10054658Term: ThalassemiaSystem Organ Class: 100000004850MedDRA version: 17.0Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 100000004864EUCTR2013-004167-32-FRovartis Pharma Services AG150
进行中（未招募）
1 期
Study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients (2-<18 years old) with iron overloadEUCTR2013-004739-55-FRovartis Pharma Services AG240
进行中（未招募）
1 期
AEUCTR2013-004167-32-ITOVARTIS FARMA S.p.A150
进行中（未招募）
1 期
Study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients (2-<18 years old) with iron overloadEUCTR2013-004739-55-ITOVARTIS PHARMA SERVICES AG216
已完成
2 期
Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload ( CALYPSO)Pediatric Patients (2-<18 Years Old) With Iron OverloadTransfusion Dependent AnemiaD64.9LBCTR2019020197ovartis Pharma Services Inc.23